Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer.

Trial Profile

Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Temsirolimus (Primary) ; Carboplatin; Paclitaxel; Sorafenib
  • Indications Cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Oct 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.
    • 14 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 07 Jun 2016 Results analyzing the safety of combination of paclitaxel, bevacizumab and temsirolimus, presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top